This inventor holds 1 USPTO granted patent. Top assignee: Shandong University. Active years: 2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2015
Title: Baoxiang Zhao: Innovator in Stem Cell Research
Introduction
Baoxiang Zhao is a prominent inventor based in Jinan, China. He has made significant contributions to the field of stem cell research, particularly in the differentiation of embryonic stem cells. His innovative work has the potential to impact drug development and regenerative medicine.
Latest Patents
Baoxiang Zhao holds a patent for the "Application of 2, 3-dihydro-3-hydroxymethyl-6-amino-[1,4]-benzoxazine in preparation of drugs inducing embryonic stem cells to differentiate to vascular endothelial cells." This patent outlines a method where the concentration of 2,3-dihydro-3-hydroxymethyl-6-amino-[1,4]-benzoxazine is effectively used to induce mouse embryonic stem cells to differentiate into vascular endothelial cells at a concentration of 1:20 µM. The invention provides a foundation for developing drugs that can induce this differentiation, serving as an effective research tool for studying embryonic stem cells and the molecular mechanisms of blood vessel formation.
Career Highlights
Baoxiang Zhao is affiliated with Shandong University, where he conducts his research and development activities. His work is recognized for its potential applications in medical science, particularly in the areas of drug development and regenerative therapies.
Collaborations
Baoxiang Zhao collaborates with notable colleagues, including Jing Zhao and Lei Han. Their combined expertise enhances the research output and innovation in their respective fields.
Conclusion
Baoxiang Zhao's contributions to stem cell research and his innovative patent highlight his role as a key figure in advancing medical science. His work not only lays the groundwork for future research but also opens new avenues for therapeutic applications.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
